BUDZ Highlights Valuable Legacy Genetics Portfolio Following Historic Federal Schedule III Marijuana Action WEED Inc. (OTCQB:BUDZ) Positioned with Rare Landrace Strains as DOJ Announces Immediate Schedule III Pathway for Qualified Medical Marijuana Products

The U.S. DOJ and DEA announced a move to place FDA-approved and state-licensed medical marijuana products into Schedule III, marking a major shift in federal cannabis policy. BUDZ views this as a validation of its strategy to acquire and hold rare legacy genetics and intellectual property, including strains like Panama Red and Acapulco Gold.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.